Parkinson's disease, dopamine pathways, movement disorders, and neuroprotection
287 articles
Blocking an enzyme reduced brain inflammation and improved movement in mice with Parkinson's-like injury, pointing to a possible treatment target.
A UCLA study links pesticide exposure to higher Parkinson’s risk, while lab experiments suggest how the chemical may damage brain cells.
A new review argues that damaged mitochondria are a shared hub driving neuron loss across five major brain diseases, and it maps the emerging fixes.
A review explores how declining clearance of toxic fat breakdown products may contribute to Parkinson's—and why antioxidants alone may fall short.
A review of 12 trials found no clear movement benefit from dopamine drugs after stroke. The strongest trials showed essentially no improvement.
A review explores how Nrf2 could protect brain cells in Parkinson's—and why promising compounds still face major safety and delivery hurdles.
Humanin preserved dopamine release in stressed laboratory cells, suggesting a possible role in brain aging research—not a proven human treatment.
A seed-sized, wirelessly powered implant activates nerves in early testing, but benefits for chronic pain and movement disorders remain unproven.
University of Birmingham scientists found that blocking the P2X7 receptor dramatically reduces neuroinflammation in human brain tissue, opening a repurposing path for existing drugs.
A completed Phase 4 trial tests whether lithium carbonate can slow cognitive decline in older adults with mild cognitive impairment.
Max Lugavere hosts a conversation on why ADHD is underdiagnosed in women, covering hormones, nutrition, exercise, sleep, digital distraction, and saffron research.
A new review reveals how the RAGE receptor links toxic protein buildup, neuroinflammation, and synaptic collapse to accelerate dementia in Parkinson's disease.
